<DOC>
	<DOCNO>NCT02605915</DOCNO>
	<brief_summary>This Phase Ib , open-label , two-stage study two active regimen stage design evaluate safety tolerability combination treatment atezolizumab , trastuzumab , pertuzumab ( without docetaxel ) atezolizumab trastuzumab emtansine participant human epidermal growth factor receptor 2 ( HER2 ) positive metastatic breast cancer ( MBC ) locally advance early breast cancer ( EBC ) , atezolizumab doxorubicin cyclophosphamide HER2-negative breast cancer .</brief_summary>
	<brief_title>Safety Pharmacokinetics Atezolizumab Combination With Trastuzumab Emtansine With Trastuzumab Pertuzumab ( With Without Docetaxel ) Participants With HER2-Positive Breast Cancer Atezolizumab With Doxorubicin Cyclophosphamide HER2-Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically document HER2positive HER2negative ( cohort E ) breast cancer Metastatic breast cancer measurable ( Stage 1 ) early breast cancer primary tumor size great ( &gt; ) 2 centimeter ( cm ) ( Stage 2 ) Eastern cooperative oncology group ( ECOG ) perform status 0 , 1 2 ; 0 1 ( cohort E ) Life expectancy 12 week Adequate hematologic endorgan function Left ventricular ejection fraction great equal ( &gt; = ) 50 percentage ( % ) ; &gt; =55 % ( cohort E ) Known central nervous system ( CNS ) disease , except treat asymptomatic CNS metastases Leptomeningeal disease Pregnancy lactation History autoimmune disease Prior allogeneic stem cell solid organ transplantation Positive test human immunodeficiency virus ( HIV ) Active hepatitis B hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>